BACKGROUND: Atherogenic dyslipoproteinemia is one of the most important risk factor for atherosclerotic changes development. Hypothyroidism is one of the most common causes of secondary dyslipidemias which results from reduced LDL clearance and therefore raised levels of LDL and apoB. Association between small dense LDL (sdLDL) presentation and thyroid status has been examinated using polyacrylamide gel electrophoresis for lipoprotein subfractions evaluation. METHODS: 40 patients with diagnosed autoimmune hypothyroidism and 30 patients with autoimmune hyperthyroidism were treated with thyroxine replacement or thyreo-suppressive treatment. In both groups lipid profiles, LDL subractions, apolipoproteins (apoA1, apoB), apoA1/apoB ratio and atherogenic index of plazma (AIP) were examined before treatment and in state of euthyreosis. RESULTS: Thyroxine replacement therapy significantly reduced levels of total cholesterol (TC), LDL, triglycerides (TG) and also decreased levels of sdLDL (8,55±11,671 vs 0,83±1,693mg/dl; p<0,001), apoB and AIP. For estimation of atherogenic lipoprotein profile existence an AIP evaluation seems to be better than apoB measurement because of the more evident relationship with sdLDL (r=0,538; p<0,01). Thyreo-suppressive therapy significantly increased levels of TC, LDL, TG and apoB. The sdLDL was not found in hyperthyroid patients. CONCLUSIONS: Atherogenic lipoprotein profile was present in 52.5% of hypothyroid subjects, which is higher prevalence than in normal, age-related population. Substitution treatment leads to an improvement of the lipid levels, TG, apoB, AIP and LDL subclasses. It significantly changed the presentation of sdLDL - we noticed shift to large, less atherogenic LDL particles. Significantly positive correlation between sdLDL and TAG; sdLDL and VLDL alerts to hypertriglyceridemia as a major cardiovascular risk factor.

Department of Cardiovascular Diseases International Clinical Research Center St Anne's University Hospital and Masaryk University Pekarska 53 Brno 656 91 Czech Republic

See more in PubMed

Rizzo M, Berneis K. Low-density lipoprotein size and cardiovascular risk assessment. QJM. 2006;99:1–14. doi: 10.1093/qjmed/hci154. PubMed DOI

Fisher WR. Heterogenity of plasma low density lipoproteins: manifestation of the physiologic phenomenon in man. Metabolism. 1983;32:283–291. doi: 10.1016/0026-0495(83)90194-4. PubMed DOI

Lamarche B, Lemieux I, Despres JP. The small, dense LDL phenotype and the risk of coronary heart disease: epidemiology, patho-physiology and therapeutic aspects. Diabetes Metab. 1999;25:199–211. PubMed

Lamarche B, Tchernof A, Moorjani S, Cantin B, Dagenais GR, Lupien PJ, Després JP. Small dense low-density lipoprotein particles as a predictor of the risk of ischemic heart Disease in men. Prospective results from the Quebec Cardiovascular study. Circulation. 1997;95:69–75. doi: 10.1161/01.CIR.95.1.69. PubMed DOI

Sacks FM, Campos H. Clinical review 163: Cardiovascular endocrinology 4: Low-density lipoprotein size and cardiovascular disease: a reappraisal. J Clin Endocrinol Metab. 2003;88:4525–4532. doi: 10.1210/jc.2003-030636. PubMed DOI

Annonymous Executive summary of the third report of The National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) JAMA. 2001;285:2486–2497. doi: 10.1001/jama.285.1.92-JMS0103-4-1. PubMed DOI

Berneis KK, Kraus RM. Metabolic origins and clinical significance of LDL heterogenity. J Lipid Res. 2002;43:1363–1379. doi: 10.1194/jlr.R200004-JLR200. PubMed DOI

Rizzo M, Berneis K, Corrado E, Novo S. The significance of low-density-lipoproteins size in vascular disease. Int Angiol. 2006;25:4–9. PubMed

Nielsen LB. Transfer of low density lipoprotein into the arterial wall and risk of atherosclerosis. Atherosclerosis. 1996;123:1–15. doi: 10.1016/0021-9150(96)05802-9. PubMed DOI

Anber V, Millar JS, McConnell M, Shepherd J, Packard CJ. Interaction of very-low-density, intermediate-density, and low-density lipoproteins with human arterial wall proteoglycans. Arterioscler Thromb Vasc Biol. 1997;17:2507–2514. doi: 10.1161/01.ATV.17.11.2507. PubMed DOI

Austin MA, King MC, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation. 1990;82:495–506. doi: 10.1161/01.CIR.82.2.495. PubMed DOI

Krauss RM. Atherogenic lipoprotein phenotype and diet-gene interactions. J Nutr. 2001;131:340S–343S. PubMed

Rizzo M, Berneis K. Should we measure routinely the LDL peak particle size. Int J Cardiol. 2006;107:166–170. doi: 10.1016/j.ijcard.2005.02.035. PubMed DOI

Maki KC, Davidson MH, Marx P, Cyrowski MS, Maki A. Association between elevated plasma fibrinogen and the small, dense low-density lipoprotein phenotype among postmenopausal women. Am J Cardiol. 2000;85:451–456. doi: 10.1016/S0002-9149(99)00771-7. PubMed DOI

Festa A, D'Agostino R, Jr, Mykkanen L, Tracy R, Howard BV, Haffner SM. Low-density lipoprotein particle size is inversely related to plasminogen activator inhibitor-1 levels. The Insulin Resistance Atherosclerosis Study. Arterioscler Thromb Vasc Biol. 1999;19:605–610. doi: 10.1161/01.ATV.19.3.605. PubMed DOI

Jellinger PS, Dickey RA, Ganda OP, Mehta AE, Nguyen TT, Rodbard HW, Seibel JA, Shepherd MD, Smith DA. The american association of clinical endocrinologists, medical guidelines for clinical practice for the diagnosis and treatment of dyslipidemia and prevention of atherogenesis. Endocr Pract. 2000;6:162–204. PubMed

Packard CJ. Triacylglycerol-rich lipoproteins and the generation of small, dense low-density lipoprotein. Biochem Soc Trans. 2003;31(pt5):1066–1069. doi: 10.1042/BST0311066. PubMed DOI

Roscini AR, Lupattelli G, Siepi D, Pagliaricci S, Pirro M, Mannarino E. Low-density lipoprotein size in primary hypothyroidism. Effects of hormone replacement therapy. Ann Nutr Metab. 1999;43:374–379. doi: 10.1159/000012806. PubMed DOI

Abbas JMK, Chakraborty J, Akanji AO, Doi SAR. Hypothyroidism results in small dense LDL independent of IRS Traits and hypertriglyceridemia. Endocr J. 2008;55:381–389. doi: 10.1507/endocrj.K07E-065. PubMed DOI

Kim CS, Kang JG, Lee SJ, Ihm SH, Yoo HJ, Nam JS, Ahn CW, Kim KR. Relationship of low-density lipoprotein (LDL) particle size to thyroid function status in Koreans. Clin Endocrinol (Oxf) 2009;71:130–136. doi: 10.1111/j.1365-2265.2008.03436.x. PubMed DOI

Duntas LH, Brenta G. The effect of thyroid disorders on lipid levels and metabolism. Med Clin North Am. 2012;96:269–281. doi: 10.1016/j.mcna.2012.01.012. PubMed DOI

Ittermann T, Baumeister SE, Völzke H, Wasner C, Schminke U, Wallaschofski H, Nauck M, Lüdemann J. Are serum TSH levels associated with oxidized low-density lipoprotein? Results from the Study of Health in Pomerania. Clin Endocrinol (Oxf) 2012;76:526–532. doi: 10.1111/j.1365-2265.2011.04186.x. PubMed DOI

Regmi A, Shah B, Rai BR, Pandeya A. Serum lipid profile in patients with thyroid disorders in central Nepal. Nepal Med Coll J. 2010;12:253–256. PubMed

Teixeira Pde F, Reuters VS, Ferreira MM, Almeida CP, Reis FA, Buescu A, Costa AJ, Vaisman M. Lipid profile in different degrees of hypothyroidism and effects of levothyroxine replacement in mild thyroid failure. Transl Res. 2008;151:224–231. doi: 10.1016/j.trsl.2007.12.006. PubMed DOI

Dobiasova M, Frohlich J. The plasma parameter Log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apo-B-lipoprotein-depleted plasma (FERHDL) Clin Biochem. 2001;34:583–588. doi: 10.1016/S0009-9120(01)00263-6. PubMed DOI

Dobiasova M. Atherogenic index of plasma [Log (Triglycerides/HDL-Cholestrol)]: Theoretical and practical implications. Clin Chem. 2004;50:1113–1115. doi: 10.1373/clinchem.2004.033175. PubMed DOI

Rainwater DL, Moore PH, Shelledy WR, Dyer TD, Slifer SH. Characterization of a composite gradient gel for the electrophoretic separation of lipoproteins. J Lipid Res. 1997;38:1261–1266. PubMed

Hirano T, Ito Y, Yoshino G. Measurement of small dense low-density lipoprotein particles. J Atheroscler Thromb. 2005;12:67–72. doi: 10.5551/jat.12.67. PubMed DOI

Otvos JD, Jeyarajah EJ, Bennett DW, Krauss RM. Development of a proton nuclear magnetic resonance spectroscopic method for determining plasma lipoprotein concentrations and subspecies distributions a single, rapid measurement. Clin Chem. 1992;38:1632–1638. PubMed

Friedewald WT, Levy RI, Frederickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502. PubMed

Hoefner DM, Hodel SD, O’Brien JF, Branum EL, Sun D, Meissner I, McConnell JP. Development of a rapid quantitative method for LDL subfraction with use of the Quantimetrix Lipoprint LDL system. Clin Chem. 2001;47:266–274. PubMed

Hirany SV, Othman Y, Kutscher P, Rainwater DL, Jialal I, Devaraj S. Comparison of low-density lipoprotein size by polyacrylamide tube gel electrophoresis and polyacrylamide gradient gel electrophoresis. Am J Clin Pathol. 2003;119:439–445. doi: 10.1309/H4E6KTYUFFF23HFN. PubMed DOI

Ensign W, Hill N, Heward CB. Disparate LDL phenotypic classification among 4 different methods assessing LDL particle characteristics. Clin Chem. 2006;52:1722–1727. doi: 10.1373/clinchem.2005.059949. PubMed DOI

Van J, Pan J, Charles MA, Krauss R, Wong N, Wu X. Atherogenic lipid phenotype in a general group of subjects. Arch Pathol Lab Med. 2007;131:1679–1685. PubMed

Gazi I, Lourida ES, Filippatos T, Tsimihodimos V, Elisaf M, Tselepis AD. Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma. Clin Chem. 2005;51:2264–2273. doi: 10.1373/clinchem.2005.058404. PubMed DOI

Austin MA, Hokanson JE, Brunzell JD. Characterization of low-density lipoprotein subclasses: methodologic approaches and clinical relevance. Curr Opin Lipidol. 1994;5:395–403. doi: 10.1097/00041433-199412000-00002. PubMed DOI

Fruchart JCH, Sacks FM, Hermans MP, Assman G, Brown WV, Ceska R, Chapman MJ, Dodson PM, Fioretto P, Ginsberg HN, Kadowaki T, Lablanche JM, Marx N, Plutzky J, Reiner Z, Rosenson RS, Staels B, Stock JK, Sy R, Wanner C, Zambon A, Zimmet P. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients. Diab Vasc Dis Res. 2008;5:319–335. doi: 10.3132/dvdr.2008.046. PubMed DOI

Jenkins AJ, Rowley KG, Lyons TJ, Best JD, Hill MA, Klein RL. Lippoproteins and diabetic microvascular complications. Curr Pharm Des. 2004;10(27):3395–3418. doi: 10.2174/1381612043383188. PubMed DOI

Assmann G. Dyslipidemia and global cardiovascular risk: clinical issues. Eur Heart J Suppl. 2006;8(Suppl F):F40–46. doi: 10.1093/eurheartj/sul040. DOI

Kato M, Dote K, Sasaki S, Ueda K, Kono Y, Naganuma T, Watanabe Y, Kajikawa M, Yokoyama H, Higashi A. Clinical impact of dyslipidemia for coronary plaque vulnerability in acute coronary syndrome without metabolic syndrome. J Cardiol. 2009;54:394–401. doi: 10.1016/j.jjcc.2009.06.007. PubMed DOI

St-Pierre AC, Cantin B, Dagenais GR, Mauriege P, Bernard PM, Després JP, Lamarche B. Low-density-lipoprotein subfraction and the long-therm risk of ischemic heart disease in men: 13-year follow-up data from the Quebec Cardiovascular Study. Arterioscler Thromb Vasc Biol. 2005;25:553–559. doi: 10.1161/01.ATV.0000154144.73236.f4. PubMed DOI

Jiskra J, Limanovi Z, Antosova M. Thyroid diseases, dyslipidemia and cardiovascular risk. Vnitr Lek. 2007;53:382–385. PubMed

Hak AE, Pols HA, Visser TJ, Drexhage HA, Hofman A, Witteman JC. Subclinical hypothyreoidism is an independent risk factor for atherosclerosis and myocardial infarction in erderly women: the Rotterdam Study. Ann Intern Med. 2000;132:270–278. doi: 10.7326/0003-4819-132-4-200002150-00004. PubMed DOI

Imaizumi M, Akahoshi M, Ichimaru S, Nakashima E, Hida A, Soda M, Usa T, Ashizawa K, Yokoyama N, Maeda R, Nagataki S, Eguchi K. Risk for ischemic heart disease and all-cause mortality in subclinical hypothyroidism. J Clin Endocrinol Metab. 2004;89:3365–3370. doi: 10.1210/jc.2003-031089. PubMed DOI

Walsh JP, Bremner AP, Bulsara MK, O’Leary P, Leedman PJ, Feddema P, Michelangeli V. Subclinical thyroid dysfunction as a risk factor for cardiovascular disease. Arch Intern Med. 2005;165:2467–2472. doi: 10.1001/archinte.165.21.2467. PubMed DOI

Wanjia X, Chenggang W, Aihong W, Xiaomei Y, Jiajun Z, Chunxiao Y, Jin X, Yinglong H, Ling G. A high normal TSH level is associated with an atherogenic lipid profile in euthyroid non-smokers with newly diagnosed asymptomatic coronary heart disease. Lipids Health Dis. 2012;11:44. doi: 10.1186/1476-511X-11-44. PubMed DOI PMC

Austin MA, Breslow JL, Hennekens CH, Buring JE, Willet WC, Krauss RM. Low density lipoprotein subclass patterns and risk of myocardial infarction. JAMA. 1988;260:1917–1921. doi: 10.1001/jama.1988.03410130125037. PubMed DOI

Oravec S, Gruber K, Dostal E, Mikl J. Hyper-betalipoproteinemia LDL 1,2: A newly identified nonatherogenic hypercholesterolemia in a group of hypercholesterolemic subjects. Neuro Endocrinol Lett. 2011;32:322–327. PubMed

Castelli WP. Cholesterol and lipids in the risk of coronary artery disease – The Framingham Heart Study. Can J Cardiol. 1988;4(Suppl A):5A–10A. PubMed

Castelli WP. Epidemiology of triglycerides; a view from Framingham. Am J Cardiol. 1992;70:43–49. doi: 10.1016/0002-9149(92)91083-G. PubMed DOI

Castelli WP. The new pathophysiology of coronary artery disease. Am J Cardiol. 1998;82(Suppl 2):60–85. doi: 10.1016/S0002-9149(98)00729-2. PubMed DOI

Tan MH, Johns D, Glazer NB. Pioglitazone reduces atherogenic index of plasma in patients with type 2 diabetes. Clin Chem. 2004;50:1184–1188. doi: 10.1373/clinchem.2004.031757. PubMed DOI

Brewer HB., Jr Hypertriglyceridemia: changes in the plasma lipoproteins associated with an increased risk of cardiovascular disease. Am J Cardiol. 1999;83(9B):3F–12F. doi: 10.1016/S0002-9149(99)00308-2. PubMed DOI

Ooi EMM, Barrett PHR, Chan DC, Watts GF. Apolipoprotein C-III: understanding an emerging cardiovascular risk factor. Clin Sci. 2008;114(10):611–624. doi: 10.1042/CS20070308. PubMed DOI

Zheng C, Khoo C, Furtado J, Sacks FM. Apolipoprotein C-III and the metabolic basis for hypertriglyceridemia and the dense LDL phenotype. Circulation. 2010;121(15):1722–1734. doi: 10.1161/CIRCULATIONAHA.109.875807. PubMed DOI PMC

Sniderman AD, Rosenbloom M. If apoB is so good, why isn’t everybody measuring it? One reason why we need The Netherlands Journal of Medicine! Neth J Med. 2005;63:232–235. PubMed

Albrink MJ, Man EB. Serum triglycerides in coronary artery disease. Arch Intern Med. 1959;103:4–8. doi: 10.1001/archinte.1959.00270010010002. PubMed DOI

Sprecher DL. Triglycerides as a risk factor for coronary artery disease. Am J Cardiol. 1998;82:49U–56U. doi: 10.1016/S0002-9149(98)00953-9. PubMed DOI

Holewijn S, Sniderman AD, den Heijer M, Swinkels DW, Stalenhoef AF, de Graaf J. Application and validation of a diagnostic algorithm for the atherogenic apoB dyslipoproteinemias: ApoB dyslipoproteinemias in a Dutch population-based study. Eur J Clin Invest. 2011;41:423–33. doi: 10.1111/j.1365-2362.2010.02426.x. PubMed DOI

Austin MA, King MC, Vranizan KM, Newman B, Krauss RM. Inheritance of low-density lipoprotein subclass patterns: results of complex segregation analysis. Am J Hum Genet. 1988;43:838–846. PubMed PMC

Campos H, Blijlevens E, McNamara JR, Ordovas JM, Posner BM, Wilson PW, Castelli WP, Schaefer EJ. LDL particle size distribution. Results from the Framingham Offspring Study. Arterioscler Thromb. 1992;12:1410–9. doi: 10.1161/01.ATV.12.12.1410. PubMed DOI

Biondi B. How could we improve the increased cardiovascular mortality in patients with overt and subclinical hyperthyroidism? Eur J Endocrinol. 2012;167:295–299. doi: 10.1530/EJE-12-0585. PubMed DOI

Yang LB, Jiang DQ, Qi WB, Zhang T, Feng YL, Gao L, Zhao J. Subclinical hyperthyroidism and the risk of cardiovascular events and all-cause mortality: an updated meta-analysis of cohort studies. Eur J Endocrinol. 2012;167:75–84. doi: 10.1530/EJE-12-0015. PubMed DOI

Brandt F, Green A, Hegedüs L, Brix TH. A critical review and meta-analysis of the association between overt hyperthyroidism and mortality. Eur J Endocrinol. 2011;165:491–497. doi: 10.1530/EJE-11-0299. PubMed DOI

Effect of short term aerobic exercise on fasting and postprandial lipoprotein subfractions in healthy sedentary men